Expertise in
34
conditions

Dr. Jared D. Acoba

Oncology
Office
321 N Kuakini St Ste 404, 
Honolulu, HI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
34
conditions
Office
321 N Kuakini St Ste 404, 
Honolulu, HI 

Overview

Jared Acoba is an Oncologist practicing medicine in Honolulu, Hawaii.

Dr. Acoba is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Gastrostomy.

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 22 clinical trials. Dr. Acoba is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in HI

Hospital Affiliations

Molokai General Hospital
The Queens Medical Center
Kuakini Medical Center
North Hawaii Community Hospital, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AlohaCare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Hawaii Medical Assurance Association
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Office
321 N Kuakini St Ste 404, Honolulu, HI 96817
Other Locations
Queen's Cancer Center Pob1
1380 Lusitana St Ste 608, Honolulu, HI 96813

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Enrollment Status: Recruiting
Publish Date: May 29, 2026
Intervention Type: Procedure, Other
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
View 9 Less Clinical Trials

41 Total Publications

Validation of 3 high-risk resectable hepatocellular carcinoma models.
Validation of 3 high-risk resectable hepatocellular carcinoma models.
Journal: Translational gastroenterology and hepatology
Published: August 04, 2025
Similar Doctors
Expertise in
5
conditions
Expertise in
5
conditions
Referral may be required

State Of Hawaii Department Of Health

701 Ilalo St, 
Honolulu, HI 
 (5.0 miles away)
808-586-5854
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naoto Ueno is an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Ueno is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and PIK3CA-Related Overgrowth Spectrum. Dr. Ueno is currently accepting new patients.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Office

1319 Punahou St Ste 640, 
Honolulu, HI 
 (4.4 miles away)
808-983-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Carney is an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Carney is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Tubal Ligation, and Hormone Replacement Therapy (HRT). Dr. Carney is currently accepting new patients.

Expertise in
17
conditions
Dr. Fariba Navid
Hematology | Oncology
Expertise in
17
conditions
Dr. Fariba Navid
Hematology | Oncology
Referral may be required

Children's Hospital Los Angeles

550 S Beretania St Ste 201, 
Honolulu, HI 
 (3.1 miles away)
323-660-2450
Languages Spoken:
English
See accepted insurances

Fariba Navid is a Hematologist and an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Navid is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroblastoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Jared D. Acoba

How do I make an appointment with Dr. Jared D. Acoba?

You can book an appointment with Dr. Jared D. Acoba by calling their office at 808-531-8521. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jared D. Acoba a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jared D. Acoba is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jared D. Acoba specialize in?

While Dr. Jared D. Acoba is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jared D. Acoba participate in research or clinical trials?

Yes. Dr. Jared D. Acoba has published 41 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Jared D. Acoba's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jared D. Acoba accept my insurance?

Dr. Jared D. Acoba accepts most major insurance plans, including Aetna and AlohaCare. We recommend calling the office directly at 808-531-8521 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acoba's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile